Get to know our clinical trials
Randomized, blinded, placebo-controlled phase 2 clinical trial investigating the efficacy and safety of visugromab and nivolumab, with or without docetaxel, compared with docetaxel alone.
THE AIM OF THIS CLINICAL TRIAL IS TO DETERMINE THE EFFICACY OF A NEW DRUG CALLED “VISUGROMAB” (ALSO KNOWN AS “CT-L002”) AND ITS SAFETY WHEN ADMINISTERED IN COMBINATION WITH NIVOLUMAB AND DOCETAXEL. CT-L002 AND NIVOLUMAB HELP THE IMMUNE SYSTEM FIGHT CANCER. DOCETAXEL INTERFERES WITH THE GROWTH OF CANCER CELLS, LEADING TO THEIR DESTRUCTION. CT-L002 HAS NOT YET BEEN APPROVED FOR ANY PATIENTS OUTSIDE RESEARCH STUDIES.
Technical Summary
- RANDOMIZED, BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY INVESTIGATING THE EFFICACY AND SAFETY OF VISUGROMAB AND NIVOLUMAB, WITH OR WITHOUT DOCETAXEL, COMPARED WITH DOCETAXEL ALONE, AS SECOND-LINE TREATMENT IN PARTICIPANTS WITH METASTATIC, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (GDFATHER-NSCLC-02).
- Code EudraCT: 2024-516794-70
- Protocol number: CTL-002-004
- Promoter: CatalYm GmbH
- Molecule/Drug: Visugromab y nivolumab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.